<?xml version="1.0" encoding="UTF-8"?>
<snippetsTree>
 <snippets file="4-part\PMC7183126\results\search\drugs\results.xml">
  <result pre="Protocol HIV-1 integrase resistance associated mutations and the use of" exact="dolutegravir" post="in Sub-Saharan Africa: a systematic review and meta-analysis protocol"/>
  <result pre="settings. This review aims at synthesizing the current knowledge on" exact="dolutegravir" post="use and integrase resistance-associated mutations found before the wide"/>
  <result pre="randomized and non-randomized trials, cohort, and cross-sectional studies published on" exact="dolutegravir" post="use or integrase resistance-associated mutations in Sub-Saharan Africa. Searches"/>
  <result pre="of adults and/or children exposed to integrase inhibitors-based therapies; especially" exact="dolutegravir" post="or raltegravir (which is our intervention of interest as"/>
  <result pre="and/or children exposed to integrase inhibitors-based therapies; especially dolutegravir or" exact="raltegravir" post="(which is our intervention of interest as compared to"/>
  <result pre="inhibitors by contributing to current knowledge on the use of" exact="dolutegravir" post="and/or raltegravir (especially for neonates) in Sub-Saharan Africa. Results"/>
  <result pre="contributing to current knowledge on the use of dolutegravir and/or" exact="raltegravir" post="(especially for neonates) in Sub-Saharan Africa. Results will therefore"/>
  <result pre="host cells. There are currently five drugs in this class;" exact="raltegravir" post="(RAL), elvitegravir (EVG), dolutegravir (DTG), cabotegravir (CAB), bictegravir (BIC)"/>
  <result pre="There are currently five drugs in this class; raltegravir (RAL)," exact="elvitegravir" post="(EVG), dolutegravir (DTG), cabotegravir (CAB), bictegravir (BIC) [1–7]. These"/>
  <result pre="currently five drugs in this class; raltegravir (RAL), elvitegravir (EVG)," exact="dolutegravir" post="(DTG), cabotegravir (CAB), bictegravir (BIC) [1–7]. These INSTIs are"/>
  <result pre="Efficacy and safety of switching to fixed-dose bictegravir, emtricitabine, and" exact="tenofovir" post="alafenamide from boosted protease inhibitor-based regimens in virologically suppressed"/>
  <result pre="C, Podzamczer D, Tebas P, et al. Bictegravir, emtricitabine, and" exact="tenofovir" post="alafenamide versus dolutegravir, abacavir, and lamivudine for initial treatment"/>
  <result pre="al. Bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir, abacavir, and" exact="lamivudine" post="for initial treatment of HIV-1 infection (GS-US-380-1489): a double-blind,"/>
  <result pre="Lippincott Williams and Wilkins; 2017. p. 343–350. 8.AkihisaEKawauchi-MikiSMikiSSatoAWakasa-MorimotoCFujiwaraTet al.Effects of" exact="raltegravir" post="or elvitegravir resistance signature mutations on the barrier to"/>
  <result pre="and Wilkins; 2017. p. 343–350. 8.AkihisaEKawauchi-MikiSMikiSSatoAWakasa-MorimotoCFujiwaraTet al.Effects of raltegravir or" exact="elvitegravir" post="resistance signature mutations on the barrier to dolutegravir resistance"/>
  <result pre="raltegravir or elvitegravir resistance signature mutations on the barrier to" exact="dolutegravir" post="resistance in vitroAntimicrob Agents Chemother.20155952596260610.1128/AAC.04844-1425691633 9.GantnerPLeeGQReyDMespledeTPartisaniMCheneauCet al.Dolutegravir reshapes the"/>
  <result pre="reservoirsJ Antimicrob Chemother.20187341045105310.1093/jac/dkx47529244129 10.Wainberg MA, Han Y-S, Mesplède T. Might" exact="dolutegravir" post="be part of a functional cure for HIV? Can"/>
  <result pre="López-Cortés L, et al. Switching to fixed-dose bictegravir, emtricitabine, and" exact="tenofovir" post="alafenamide from dolutegravir plus abacavir and lamivudine in virologically"/>
  <result pre="al. Switching to fixed-dose bictegravir, emtricitabine, and tenofovir alafenamide from" exact="dolutegravir" post="plus abacavir and lamivudine in virologically suppressed adults with"/>
  <result pre="to fixed-dose bictegravir, emtricitabine, and tenofovir alafenamide from dolutegravir plus" exact="abacavir" post="and lamivudine in virologically suppressed adults with HIV-1: 48 week"/>
  <result pre="bictegravir, emtricitabine, and tenofovir alafenamide from dolutegravir plus abacavir and" exact="lamivudine" post="in virologically suppressed adults with HIV-1: 48 week results of"/>
  <result pre="DeJesus E, Stellbrink H-JJ, et al. Coformulated bictegravir, emtricitabine, and" exact="tenofovir" post="alafenamide versus dolutegravir with emtricitabine and tenofovir alafenamide, for"/>
  <result pre="H-JJ, et al. Coformulated bictegravir, emtricitabine, and tenofovir alafenamide versus" exact="dolutegravir" post="with emtricitabine and tenofovir alafenamide, for initial treatment of"/>
  <result pre="al. Coformulated bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir with" exact="emtricitabine" post="and tenofovir alafenamide, for initial treatment of HIV-1 infection"/>
  <result pre="bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir with emtricitabine and" exact="tenofovir" post="alafenamide, for initial treatment of HIV-1 infection (GS-US-380–1490): a"/>
 </snippets>
</snippetsTree>
